nilutamide

DRUG11 trials

Sponsors

Novartis Pharma AG, NCIC Clinical Trials Group, M.D. Anderson Cancer Center, National Cancer Institute (NCI), SWOG Cancer Research Network

Conditions

Adenocarcinoma of the ProstateCastration Levels of TestosteroneMetastatic Prostatic AdenocarcinomaPSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)Prostate AdenocarcinomaProstate CancerRecurrent Prostate CancerRecurrent Prostate Carcinoma

Phase 1

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

TerminatedNCT00512668

National Cancer Institute (NCI)Adenocarcinoma of the Prostate, Recurrent Prostate Cancer

Start: 2007-09-30Updated: 2013-01-07

Phase 2

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

CompletedNCT00020254

National Cancer Institute (NCI)Prostate Cancer

Start: 2000-06-30Updated: 2015-04-29

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

CompletedNCT00028769

SWOG Cancer Research NetworkProstate Cancer

Start: 2001-12-31End: 2011-07-31Updated: 2013-07-16

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

TerminatedNCT00918385

Duke UniversityProstate Cancer

Start: 2009-05-31End: 2013-08-31Updated: 2014-10-29

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Active, not recruitingNCT01786265

M.D. Anderson Cancer CenterProstate Adenocarcinoma, Recurrent Prostate Carcinoma

Start: 2013-02-05End: 2027-02-01Target: 310Updated: 2026-02-20

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

CompletedNCT03070886

NRG OncologyStage III Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage I Prostate Adenocarcinoma AJCC v7

Start: 2017-04-05End: 2025-10-31Updated: 2026-01-14

Phase 3

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

CompletedNCT00003653

NCIC Clinical Trials GroupProstate Cancer

Start: 1999-01-05End: 2013-01-10Updated: 2021-06-23

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

CompletedNCT00002633

NCIC Clinical Trials GroupProstate Cancer

Start: 1995-02-08End: 2012-01-06Updated: 2020-04-03

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

CompletedNCT00002855

M.D. Anderson Cancer CenterProstate Cancer

Start: 1996-08-31End: 2005-06-30Updated: 2018-10-31

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

RecruitingNCT03678025

SWOG Cancer Research NetworkCastration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IVA Prostate Cancer AJCC v8 +2

Start: 2018-09-24End: 2031-10-01Target: 1273Updated: 2025-09-11

PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Active, not recruitingCTIS2023-507970-42-00

Novartis Pharma AGPSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)

Start: 2021-03-31Target: 445Updated: 2026-01-26

Related Papers

Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial

Cancer Control2022-08-18

Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naïve prostate cancer (M0HNPC).

Journal of Clinical Oncology2022-02-162 citations

Metastatic prostate cancer men’s attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study

BMJ Open2021-11-013 citations

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer

JAMA Oncology2021-02-12141 citations

The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.

2020-12-3128 citations

MP53-11 COMPARATIVE EFFICACY OF LOCAL VERSUS SYSTEMIC SALVAGE THERAPIES FOR RADIO-RECURRENT PROSTATE CANCER: A SUB-ANALYSIS OF CCTG PR-7

The Journal of Urology2020-04-01

Comparative efficacy of local versus systemic salvage therapies for recurrent prostate cancer after primary radiotherapy.

Journal of Clinical Oncology2020-02-19

A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent non metastatic hormone naïve prostate cancer (M0HNPC).

Journal of Clinical Oncology2018-05-204 citations

MP73-04 THE ASSOCIATION BETWEEN STATIN USE AND OUTCOMES IN PATIENTS INITIATING ANDROGEN DEPRIVATION THERAPY

The Journal of Urology2015-03-312 citations

The association between statin use and outcomes in patients initiating androgen deprivation therapy.

Journal of Clinical Oncology2015-03-015 citations

Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.

2015-01-2946 citations

Intermittent androgen suppression for rising PSA level after radiotherapy.

2012-09-01349 citations

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

2011-11-02404 citations